FDA Clears New Gene Therapy for Spinal Muscular Atrophy — Big Hope for Older Children & Adults

A groundbreaking approval: the U.S. FDA has cleared Itvisma, a one-time gene therapy for patients aged 2 years and older with Spinal Muscular Atrophy (SMA), offering a potential lifeline for those previously beyond the reach of existing treatments.